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Introduction
Despite numerous publications discussing the problem, the effects of pregnancy on the progress of malignancy 
and its prognosis, the effects of the disease and the applied therapy on the foetus, the optimal timing of chemotherapy 
and possible necessity for early termination of pregnancy raise controversies. Hodgkin lymphoma (HL) affects one in 
1000–6000 pregnancies. The treatment of choice is chemotherapy combined with radiotherapy has become established 
international standards of care for advanced HL. 
Objectives
Prognosis in patients with HL during pregnancy resembles that observed in non-pregnant women, provided that 
proper therapeutic management is applied. There are no prospective trials for the management of HL in pregnancy, but 
a number of published case reports, case series and case cohorts were reviewed earlier.
Material and methods
Nine pregnant patients at the age of 20 and 28 (median 24.1), with Hodgkin lymphoma treated between 1997 and 
2014 in the Department of Hematology and Bone Marrow Transplantation Poznan University of Medical Sciences, were 
enrolled in this study. HL was diagnosed between 11th and 30th week of pregnancy on the basis of histopatological 
evaluation of the excised lymph node. We determined the clinical stage according to the Ann Arbor classification modified 
in Cotswolds. Characteristics of the examined group, regiment of chemotherapy applied, type of clinical response and 
performance status of newborns after birth are showed in Table 1.
Results and conclusions
Our study of the group of 9 patients confirmed high safety of using ABVD chemotherapy in patients with Hodgkin 
lymphoma, either in the early or in late period of pregnancy. Analysis of various clinical cases presented above confirms 
high efficacy and safety of the applied antineoplastic treatment in pregnant patients with HL. An effort should be made 
to determine the stage of the disease and presence of unfavourable prognostic factors precisely.
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Table 1. Characteristics of the examined group 
Item Patient age [years] Trimester of pregnancy
HL 
type CS* IPS Applied treatment
Result of 
treatment
Delivery 
[week]
Apgar 
score
Birth 
weight [g]
1. 28 I MC IIA 2
4 x ABVD
unexpected pregnancy
4 x ABVD
2 x ESHAP
2 x IVE
auto-HSCT
relapse
3 x GDP
auto-HSCT
PR
PR
Progression
PR
CR
CR
CR
40 10 3400
2. 23 II NS IIIA 1 8 x ABVD CR 32 8 1800
3. 22 II MC IIB 2 7 x ABVD CR 37 10 3100
4. 24 II NS IIIB 2 8 x ABVD CR 36 10 2900
5. 25 II NS IVA 5
abortion
8 x ABVD
diagnosis of pregnancy
2 x DHAP
PR
CR
36 10 2800
6. 26 II NS IVB 5
ABVD 6x
ESHAP 3x 
auto-HSCT
resistance
CR
CR
36 10 2700
7. 25 II NS IVB 3 4 x BEACOPP CR 38 8 3100
8. 24 II NS IVB 2 8 x ABVD CR 38 10 3200
9. 20 II NLPHL IVB 3 4 x ABVD2 x BEACOPP
PR
CR 38 10 3400
HL —  Hodgkin lymphoma; MC —  mixed cellularity; NS —  nodular sclerosis; NLPHL —  lymphocyte-predominant Hodgkin lymphoma; CS —  clinical stage; IPF —  
International Prognostic Score; PR —  partial remission; CR complete remission; ABVD —  doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP —  bleomycin, 
etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone; ESHAP —  etoposide, methylprednisolone, cytarabine, cisplatin; IVE —  ifosfamide, 
epirubicin, etoposide; GDP —  gemcitabine, dexamethasone, cisplatin; auto-HSCT —  autologous hematopoietic stem cell transplantation 
* clinical stage according to Ann Arbor classification modified in Cotswolds
